
Commentary|Videos|December 14, 2024
Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer
Author(s)Erica L. Mayer, MD, MPH
Fact checked by: Ashling Wahner , Chris Ryan
Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.
Advertisement
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School, discusses findings with the use of neoadjuvant niraparib (Zejula) plus dostarlimab-gxly (Jemperli) from the estrogen receptor (ER)–positive, HER2-negative, BRCA/PALB2-mutated breast cancer cohort of the phase 2 TBCRC 056 trial (NCT04584255).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































